{"DataElement":{"publicId":"14675082","version":"1","preferredName":"Decorporation Agent Administered Type","preferredDefinition":"A description of the decorporation agent that was administered.","longName":"4746837v1.00:14675068v1.00","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"4746837","version":"1","preferredName":"Radionuclide Decorporation Agent Administered","preferredDefinition":"Any agent that is able to prevent absorption or facilitate the removal of internal radionuclide contamination._The act of having given something (e.g., a medication or test).","longName":"4746835v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"4746835","version":"1","preferredName":"Radionuclide Decorporation Agent","preferredDefinition":"Any agent that is able to prevent absorption or facilitate the removal of internal radionuclide contamination.","longName":"C120558","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radionuclide Decorporation Agent","conceptCode":"C120558","definition":"Any agent that is able to prevent absorption or facilitate the removal of internal radionuclide contamination.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11910A63-39D8-012F-E050-BB89AD432D38","latestVersionIndicator":"Yes","beginDate":"2015-03-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-18","modifiedBy":"ONEDATA","dateModified":"2015-03-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"11910A63-39E6-012F-E050-BB89AD432D38","latestVersionIndicator":"Yes","beginDate":"2015-03-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"14675068","version":"1","preferredName":"Radionuclide Decorporation Agent Type","preferredDefinition":"Any agent that is able to prevent absorption or facilitate the removal of internal radionuclide contamination._Something distinguishable as an identifiable class based on common qualities.","longName":"14675068v1.00","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"120","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Aluminum carbonate","valueDescription":null,"ValueMeaning":{"publicId":"14675069","version":"1","preferredName":"Aluminum Carbonate","longName":"14675069v1.00","preferredDefinition":"The aluminum salt form of carbonic acid, an antacid with phosphate binding activity. Upon oral administration of aluminum carbonate, aluminum is able to bind to phosphate in the intestines, including the radionuclide phosphate P-32, thereby preventing phosphate uptake.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aluminum Carbonate","conceptCode":"C120559","definition":"The aluminum salt form of carbonic acid, an antacid with phosphate binding activity. Upon oral administration of aluminum carbonate, aluminum is able to bind to phosphate in the intestines, including the radionuclide phosphate P-32, thereby preventing phosphate uptake.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E9BFEC6-1E9F-5D1C-E063-731AD00A1DFB","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EAC-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Aluminum hydroxide","valueDescription":null,"ValueMeaning":{"publicId":"2575995","version":"1","preferredName":"Aluminum Hydroxide","longName":"2575995","preferredDefinition":"An inorganic compound containing aluminium.  Used in various immunologic preparations to improve immunogenicity, aluminum hydroxide adjuvant consists of aluminium hydroxide gel in a saline solution.  In vaccines, this agent binds to the protein conjugate, resulting in improved antigen processing by the immune system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aluminum Hydroxide","conceptCode":"C39707","definition":"An inorganic compound containing aluminum.  Used in various immunologic preparations to improve immunogenicity, aluminum hydroxide adjuvant consists of aluminum hydroxide gel in a saline solution.  In vaccines, this agent binds to the protein conjugate, resulting in improved antigen processing by the immune system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5E8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"REEVESD","dateModified":"2005-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EAD-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Barium sulfate","valueDescription":null,"ValueMeaning":{"publicId":"2577725","version":"1","preferredName":"Barium Sulfate","longName":"2577725","preferredDefinition":"The sulfate salt of barium, an alkaline, divalent metal.  Barium sulfate is quite insoluble in water, and is used as a radiopaque agent to diagnose gastrointestinal medical conditions.  Barium sulfate is taken by mouth or given rectally. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Barium Sulfate","conceptCode":"C28859","definition":"The sulfate salt of barium, an alkaline, divalent metal.  Barium sulfate is quite insoluble in water, and is used as a radiopaque agent to diagnose gastrointestinal medical conditions.  Barium sulfate is taken by mouth or given rectally. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCAA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EAE-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Calcium carbonate","valueDescription":null,"ValueMeaning":{"publicId":"2577780","version":"1","preferredName":"Calcium Carbonate","longName":"2577780","preferredDefinition":"The carbonic salt of calcium (CaCO3). Calcium carbonate is used therapeutically as a phosphate buffer in hemodialysis, as an antacid in gastric hyperacidity for temporary relief of indigestion and heartburn, and as a calcium supplement for preventing and treating osteoporosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcium Carbonate","conceptCode":"C332","definition":"The carbonic salt of calcium (CaCO3). Calcium carbonate is used therapeutically as a phosphate buffer in hemodialysis, as an antacid in gastric hyperacidity for temporary relief of indigestion and heartburn, and as a calcium supplement for preventing and treating osteoporosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCE1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EAF-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Calcium disodium EDTA","valueDescription":null,"ValueMeaning":{"publicId":"14675070","version":"1","preferredName":"Edetate Calcium Disodium","longName":"14675070v1.00","preferredDefinition":"Contracted name for a salt of ethylenediaminetetraacetate, an agent used as a chelator of lead and some other heavy metals. C10H12CaN2Na2O8.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Edetate Calcium Disodium","conceptCode":"C334","definition":"Contracted name for a salt of ethylenediaminetetraacetate, an agent used as a chelator of lead and some other heavy metals. C10H12CaN2Na2O8.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E9BFEC6-1EA0-5D1C-E063-731AD00A1DFB","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EB0-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Calcium DTPA by nebulizer","valueDescription":null,"ValueMeaning":{"publicId":"14675071","version":"1","preferredName":"Nebulizer Pentetate Calcium","longName":"14675071v1.00","preferredDefinition":"A device for administration of medicinal substance(s) in form of a liquid mist to the patient airways. Nebulizer pumps air or oxygen through a liquid medicine to turn it into a vapor, which is then inhaled by the patient._The calcium salt form of diethylene triamine pentaacetate (Ca-DTPA or pentetate calcium), with chelating activity. Upon administration, Ca-DTPA loses the Ca ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Ca ions. Specifically, this agent is able to bind to and form strong complexes with radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. enhances radionuclide excretion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nebulizer","conceptCode":"C28172","definition":"A device for administration of medicinal substance(s) in form of a liquid mist to the patient airways. Nebulizer pumps air or oxygen through a liquid medicine to turn it into a vapor, which is then inhaled by the patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pentetate Calcium","conceptCode":"C120569","definition":"The calcium salt form of diethylene triamine pentaacetate (Ca-DTPA or pentetate calcium), with chelating activity. Upon administration, Ca-DTPA loses the Ca ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Ca ions. Specifically, this agent is able to bind to and form strong complexes with radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. enhances radionuclide excretion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E9BFEC6-1EA1-5D1C-E063-731AD00A1DFB","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EB1-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Calcium DTPA IV","valueDescription":null,"ValueMeaning":{"publicId":"14675072","version":"1","preferredName":"Intravenous Route of Administration Pentetate Calcium","longName":"14675072v1.00","preferredDefinition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index._The calcium salt form of diethylene triamine pentaacetate (Ca-DTPA or pentetate calcium), with chelating activity. Upon administration, Ca-DTPA loses the Ca ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Ca ions. Specifically, this agent is able to bind to and form strong complexes with radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. enhances radionuclide excretion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pentetate Calcium","conceptCode":"C120569","definition":"The calcium salt form of diethylene triamine pentaacetate (Ca-DTPA or pentetate calcium), with chelating activity. Upon administration, Ca-DTPA loses the Ca ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Ca ions. Specifically, this agent is able to bind to and form strong complexes with radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion. enhances radionuclide excretion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E9BFEC6-1EA2-5D1C-E063-731AD00A1DFB","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EB2-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Calcium gluconate","valueDescription":null,"ValueMeaning":{"publicId":"2577782","version":"1","preferredName":"Calcium Gluconate","longName":"2577782","preferredDefinition":"The gluconate salt of calcium. An element or mineral necessary for normal nerve, muscle, and cardiac function, calcium as the gluconate salt helps to maintain calcium balance and prevent bone loss when taken orally. This agent may also be chemopreventive for colon and other cancers. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcium Gluconate","conceptCode":"C336","definition":"The gluconate salt of calcium. An element or mineral necessary for normal nerve, muscle, and cardiac function, calcium as the gluconate salt helps to maintain calcium balance and prevent bone loss when taken orally. This agent may also be chemopreventive for colon and other cancers. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCE3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EB3-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Calcium phosphate","valueDescription":null,"ValueMeaning":{"publicId":"14675073","version":"1","preferredName":"Calcium Phosphate","longName":"14675073v1.00","preferredDefinition":"The calcium salt of phosphoric acid with widely used applications. This agent can be used as a countermeasure for exposure to strontium and radium radionuclides. Upon oral uptake, calcium phosphate competes for and blocks the absorption of radium (Ra-226) and strontium (Sr-90) in the gastrointestinal (GI) tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calcium Phosphate","conceptCode":"C120560","definition":"The calcium salt of phosphoric acid with widely used applications. This agent can be used as a countermeasure for exposure to strontium and radium radionuclides. Upon oral uptake, calcium phosphate competes for and blocks the absorption of radium (Ra-226) and strontium (Sr-90) in the gastrointestinal (GI) tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E9BFEC6-1EA3-5D1C-E063-731AD00A1DFB","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EB4-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Deferoxamine","valueDescription":null,"ValueMeaning":{"publicId":"13634040","version":"1","preferredName":"Deferoxamine Mesylate","longName":"13634040v1.00","preferredDefinition":"The mesylate salt of an iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and ferrioxamine, a water-soluble complex excreted by the kidneys and in the feces via the bile. This agent does not readily chelate iron bound to transferrin, hemoglobin, myoglobin or cytochrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Deferoxamine Mesylate","conceptCode":"C417","definition":"The mesylate salt of an iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and ferrioxamine, a water-soluble complex excreted by the kidneys and in the feces via the bile. This agent does not readily chelate iron bound to transferrin, hemoglobin, myoglobin or cytochrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC66A0FB-104B-4CB3-E053-731AD00A2519","latestVersionIndicator":"Yes","beginDate":"2023-05-23","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-23","modifiedBy":"DWARZEL","dateModified":"2023-05-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EB5-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Dimercaprol","valueDescription":null,"ValueMeaning":{"publicId":"14675074","version":"1","preferredName":"Dimercaprol","longName":"14675074v1.00","preferredDefinition":"A metal chelating agent that is used as an antidote in arsenic, gold, lead, mercury and other heavy metal poisoning. Metals form ligands in the body with the sulfhydryl groups of the pyruvate-oxidase enzyme system. This leads to an inhibition of the normal functioning of these enzymes that are dependent on free sulfhydryl groups for their activity. Dimercaprol reverses the enzyme inhibition by chelating the metal and regenerates free sulfhydryl groups, thereby preventing and reversing the metals toxic effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dimercaprol","conceptCode":"C47494","definition":"A metal chelating agent that is used as an antidote in arsenic, gold, lead, mercury and other heavy metal poisoning. Metals form ligands in the body with the sulfhydryl groups of the pyruvate-oxidase enzyme system. This leads to an inhibition of the normal functioning of these enzymes that are dependent on free sulfhydryl groups for their activity. Dimercaprol reverses the enzyme inhibition by chelating the metal and regenerates free sulfhydryl groups, thereby preventing and reversing the metals toxic effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E9BFEC6-1EA4-5D1C-E063-731AD00A1DFB","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EB6-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"D-Penicillamine","valueDescription":null,"ValueMeaning":{"publicId":"13722156","version":"1","preferredName":"Penicillamine","longName":"13722156v1.00","preferredDefinition":"A beta dimethyl analog of the amino acid cysteine.  As a degradation product of penicillin antibiotics, penicillamine chelates with heavy metals and increases their urinary excretion.  Possessing antineoplastic properties, penicillamine induces apoptosis by a p53-mediated mechanism and inhibits angiogenesis by chelating with copper, a cofactor for angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Penicillamine","conceptCode":"C729","definition":"A beta dimethyl analog of the amino acid cysteine.  As a degradation product of penicillin antibiotics, penicillamine chelates with heavy metals and increases their urinary excretion.  Possessing antineoplastic properties, penicillamine induces apoptosis by a p53-mediated mechanism and inhibits angiogenesis by chelating with copper, a cofactor for angiogenesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC9DB460-D59A-5929-E053-731AD00AD8F4","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-26","modifiedBy":"DWARZEL","dateModified":"2023-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EB7-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"PLX-R18","valueDescription":null,"ValueMeaning":{"publicId":"14675075","version":"1","preferredName":"3D-expanded Placenta-derived Cells PLX-R18","longName":"14675075v1.00","preferredDefinition":"A population of proprietary, off-the-shelf, three-dimensional (3D)-expanded, allogeneic placenta-derived stromal cells that can potentially be used to increase hematopoietic recovery from hematological disorders or after a hematopoietic stem cell transplant (HSCT). Upon intramuscular (IM) injection of placental expanded (PLX)-R18, these cells secrete a range of specific hematopoietic, regenerative proteins depending on their in vivo environment. The secreted proteins are involved in maintenance, renewal, proliferation, differentiation, and mobilization of hematopoietic progenitor cells (HPCs), and include, but are not limited to, granulocyte colony-stimulating factor (GCSF), monocyte chemoattractant protein-1 (MCP-1/CCL2), MCP-3 (CCL7), interleukin-6 (IL-6), and IL-8. This increases the number of colony-forming hematopoietic progenitors in the bone marrow, regenerates the bone marrow hematopoietic cells, and elevates and restores blood cell production.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"3D-expanded Placenta-derived Cells PLX-R18","conceptCode":"C133823","definition":"A population of proprietary, off-the-shelf, three-dimensional (3D)-expanded, allogeneic placenta-derived stromal cells that can potentially be used to increase hematopoietic recovery from hematological disorders or after a hematopoietic stem cell transplant (HSCT). Upon intramuscular (IM) injection of placental expanded (PLX)-R18, these cells secrete a range of specific hematopoietic, regenerative proteins depending on their in vivo environment. The secreted proteins are involved in maintenance, renewal, proliferation, differentiation, and mobilization of hematopoietic progenitor cells (HPCs), and include, but are not limited to, granulocyte colony-stimulating factor (GCSF), monocyte chemoattractant protein-1 (MCP-1/CCL2), MCP-3 (CCL7), interleukin-6 (IL-6), and IL-8. This increases the number of colony-forming hematopoietic progenitors in the bone marrow, regenerates the bone marrow hematopoietic cells, and elevates and restores blood cell production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E9BFEC6-1EA5-5D1C-E063-731AD00A1DFB","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EB8-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Potassium iodide","valueDescription":null,"ValueMeaning":{"publicId":"3293799","version":"1","preferredName":"Potassium Iodide","longName":"3293799","preferredDefinition":"A metal halide composed of potassium and iodide with thyroid protecting and expectorant properties. Potassium iodide can block absorption of radioactive iodine by the thyroid gland through flooding the thyroid with non-radioactive iodine and preventing intake of radioactive molecules, thereby protecting the thyroid from cancer causing radiation. In addition, this agent acts as an expectorant by increasing secretion of respiratory fluids resulting in decreased mucus viscosity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Potassium Iodide","conceptCode":"C47680","definition":"A metal halide composed of potassium and iodide with thyroid protecting and expectorant properties. Potassium iodide can block absorption of radioactive iodine by the thyroid gland through flooding the thyroid with non-radioactive iodine and preventing intake of radioactive molecules, thereby protecting the thyroid from cancer causing radiation. In addition, this agent acts as an expectorant by increasing secretion of respiratory fluids resulting in decreased mucus viscosity.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF0C3CCE-D7C1-E20C-E040-BB89AD433BC3","latestVersionIndicator":"Yes","beginDate":"2011-10-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EB9-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Potassium phosphate","valueDescription":null,"ValueMeaning":{"publicId":"7060595","version":"1","preferredName":"Potassium Phosphate","longName":"7060595","preferredDefinition":"An inorganic compound used as a laxative, dietary supplement and for electrolyte-replacement purposes. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations and numerous cellular phosphate-transfer reactions. Potassium phosphate increases fluidity of the intestinal contents by retention of water by osmotic forces, thereby indirectly inducing intestinal smooth muscle constriction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Potassium Phosphate","conceptCode":"C29373","definition":"An inorganic compound used as a laxative, dietary supplement and for electrolyte-replacement purposes. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations and numerous cellular phosphate-transfer reactions. Potassium phosphate increases fluidity of the intestinal contents by retention of water by osmotic forces, thereby indirectly inducing intestinal smooth muscle constriction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97A39E9F-9B00-4341-E053-F662850A0D2A","latestVersionIndicator":"Yes","beginDate":"2019-11-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-18","modifiedBy":"ONEDATA","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EBA-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Potassium phosphate, dibasic","valueDescription":null,"ValueMeaning":{"publicId":"14675076","version":"1","preferredName":"Potassium Phosphate, Dibasic","longName":"14675076v1.00","preferredDefinition":"The dipotassium form of phosphoric acid, that can be used as an electrolyte replenisher and with radio-protective activity. Upon oral administration, potassium phosphate is able to block the uptake of the radioactive isotope phosphorus P 32 (P-32).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Potassium Phosphate, Dibasic","conceptCode":"C66452","definition":"The dipotassium form of phosphoric acid, that can be used as an electrolyte replenisher and with radio-protective activity. Upon oral administration, potassium phosphate is able to block the uptake of the radioactive isotope phosphorus P 32 (P-32).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E9BFEC6-1EA6-5D1C-E063-731AD00A1DFB","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EBB-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Propylthiouracil","valueDescription":null,"ValueMeaning":{"publicId":"7063290","version":"1","preferredName":"Propylthiouracil","longName":"7063290","preferredDefinition":"A thiourea derivative with antithyroid property. Propylthiouracil (PTU) interferes with the oxidation of iodine possibly by interaction with peroxidase or a peroxidase-mediated complex reaction, thereby inhibiting synthesis of thyroid hormones tri-iodothyronine (T3) and thyroxine (T4). In addition, this agent inhibits the Type I 5'-deiodinase (D1), an enzyme involved in the peripheral conversion of thyroxine to tri-iodothyronine. This results in decreased plasma triodothyronine concentrations and decreased entrance of thyroxine into cells thereby reducing thyroid hormone activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Propylthiouracil","conceptCode":"C781","definition":"A thiourea derivative with antithyroid property. Propylthiouracil (PTU) interferes with the oxidation of iodine possibly by interaction with peroxidase or a peroxidase-mediated complex reaction, thereby inhibiting synthesis of thyroid hormones tri-iodothyronine (T3) and thyroxine (T4). In addition, this agent inhibits the Type I 5'-deiodinase (D1), an enzyme involved in the peripheral conversion of thyroxine to tri-iodothyronine. This results in decreased plasma triodothyronine concentrations and decreased entrance of thyroxine into cells thereby reducing thyroid hormone activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97CFA8BF-57B4-66BC-E053-F662850AF2FF","latestVersionIndicator":"Yes","beginDate":"2019-11-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-11-20","modifiedBy":"ONEDATA","dateModified":"2019-11-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EBC-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Prussian blue, insoluble","valueDescription":null,"ValueMeaning":{"publicId":"14675077","version":"1","preferredName":"Ferric Ferrocyanide","longName":"14675077v1.00","preferredDefinition":"A chelating agent with strong binding affinity for thallium, cesium, and other ions. Ferric hexacyanoferrate is used for the treatment of acute and chronic thallium and cesium poisoning. This agent is not absorbed in the gastrointestinal tract and it chelates thallium or cesium ion in the intestines. The resulting complex is eliminated via the feces.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ferric Ferrocyanide","conceptCode":"C47532","definition":"A chelating agent with strong binding affinity for thallium, cesium, and other ions. Ferric hexacyanoferrate is used for the treatment of acute and chronic thallium and cesium poisoning. This agent is not absorbed in the gastrointestinal tract and it chelates thallium or cesium ion in the intestines. The resulting complex is eliminated via the feces.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E9BFEC6-1EA7-5D1C-E063-731AD00A1DFB","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EBD-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Sevelamer","valueDescription":null,"ValueMeaning":{"publicId":"3260567","version":"1","preferredName":"Sevelamer","longName":"3260567","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sevelamer","conceptCode":"C84172","definition":"A non-absorbable polymeric amine and phosphate binding agent that can be used to prevent hyperphosphatemia. Upon oral administration, the amine groups in sevelamer become protonated in the intestines and bind to the dietary phosphate groups in the gastrointestinal (GI) tract, thereby preventing the absorption of phosphate and controlling phosphate plasma levels. In addition, sevelamer, as a phosphate binder, can be used to prevent the absorption of the radionuclide phosphorus P 32 (P-32).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9BAC718-E246-E556-E040-BB89AD43121D","latestVersionIndicator":"Yes","beginDate":"2011-08-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EBE-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Sodium alginate","valueDescription":null,"ValueMeaning":{"publicId":"14675078","version":"1","preferredName":"Sodium Alginate","longName":"14675078v1.00","preferredDefinition":"The sodium salt form of alginic acid and gum mainly extracted from the cell walls of brown algae, with chelating activity. Upon oral administration, sodium alginate binds to and blocks the intestinal absorption of various radioactive isotopes, such as radium Ra 226 (Ra-226) and strontium Sr 90 (Sr-90).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sodium Alginate","conceptCode":"C84148","definition":"The sodium salt form of alginic acid and gum mainly extracted from the cell walls of brown algae, with chelating activity. Upon oral administration, sodium alginate binds to and blocks the intestinal absorption of various radioactive isotopes, such as radium Ra 226 (Ra-226) and strontium Sr 90 (Sr-90).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E9BFEC6-1EA8-5D1C-E063-731AD00A1DFB","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EBF-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Sodium bicarbonate","valueDescription":null,"ValueMeaning":{"publicId":"7460898","version":"1","preferredName":"Sodium Bicarbonate","longName":"7460898","preferredDefinition":"The monosodium salt of carbonic acid with alkalinizing and electrolyte replacement properties. Upon dissociation, sodium bicarbonate forms sodium and bicarbonate ions. Ion formation increases plasma bicarbonate and buffers excess hydrogen ion concentration, resulting in raised blood pH.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sodium Bicarbonate","conceptCode":"C29457","definition":"The monosodium salt of carbonic acid with alkalinizing and electrolyte replacement properties. Upon dissociation, sodium bicarbonate forms sodium and bicarbonate ions. Ion formation increases plasma bicarbonate and buffers excess hydrogen ion concentration, resulting in raised blood pH.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1047D74-D734-632D-E053-4EBD850AB0BF","latestVersionIndicator":"Yes","beginDate":"2020-10-06","endDate":null,"createdBy":"COOPERJ","dateCreated":"2020-10-06","modifiedBy":"ONEDATA","dateModified":"2020-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EC0-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Sodium glycerophosphate","valueDescription":null,"ValueMeaning":{"publicId":"14675079","version":"1","preferredName":"Sodium Glycerophosphate","longName":"14675079v1.00","preferredDefinition":"The sodium salt form of an organic phosphate compound that provides phosphate for nutritional purposes. In addition, sodium glycerophosphate can be used as a phosphate diluting agent upon internal contamination with the beta-emiting radioisotope phosphate P 32 (P-32) that competes with P-32 for absorption. As sodium glycerophosphate is administered in high amounts, the absorption of P-32 is prevented or minimalized.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sodium Glycerophosphate","conceptCode":"C120561","definition":"The sodium salt form of an organic phosphate compound that provides phosphate for nutritional purposes. In addition, sodium glycerophosphate can be used as a phosphate diluting agent upon internal contamination with the beta-emiting radioisotope phosphate P 32 (P-32) that competes with P-32 for absorption. As sodium glycerophosphate is administered in high amounts, the absorption of P-32 is prevented or minimalized.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E9BFEC6-1EA9-5D1C-E063-731AD00A1DFB","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EC1-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Sodium phosphate","valueDescription":null,"ValueMeaning":{"publicId":"5626462","version":"1","preferredName":"Sodium Phosphate","longName":"5626462","preferredDefinition":"An inorganic compound used as a laxative, dietary supplement and for electrolyte-replacement purposes. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations, and numerous cellular phosphate-transfer reactions. Sodium phosphate increases fluidity of the intestinal contents by retention of water by osmotic forces, thereby indirectly inducing intestinal smooth muscle constriction. Sodium phosphate is also used in the renal excretion of hydrogen ions while promoting the reabsorption of sodium ions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sodium Phosphate","conceptCode":"C29459","definition":"An inorganic compound used as a laxative, dietary supplement and for electrolyte-replacement purposes. Phosphate, a predominant intracellular anion, plays an important role in energy storage, osteoblastic and osteoclastic activities, regulating serum calcium concentrations, and numerous cellular phosphate-transfer reactions. Sodium phosphate increases fluidity of the intestinal contents by retention of water by osmotic forces, thereby indirectly inducing intestinal smooth muscle constriction. Sodium phosphate is also used in the renal excretion of hydrogen ions while promoting the reabsorption of sodium ions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45E83254-FC65-5FF6-E053-F662850A88CF","latestVersionIndicator":"Yes","beginDate":"2017-01-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EC2-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Succimer","valueDescription":null,"ValueMeaning":{"publicId":"14675080","version":"1","preferredName":"Succimer","longName":"14675080v1.00","preferredDefinition":"An orally active mercaptodicarboxylic acid, with heavy metal chelating activity. As a strong chelator, succimer is able to bind to heavy metals, such as lead, in the bloodstream, thereby forming a water-soluble complex that can be eliminated via urinary excretion. This prevents heavy metal poisoning. In addition, succimer is able to chelate the alpha particle emitter and radionuclide polonium Po 210 ((Po-210), thereby increasing its excretion and reducing the toxic effects of Po-210.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Succimer","conceptCode":"C61953","definition":"An orally active mercaptodicarboxylic acid, with heavy metal chelating activity. As a strong chelator, succimer is able to bind to heavy metals, such as lead, in the bloodstream, thereby forming a water-soluble complex that can be eliminated via urinary excretion. This prevents heavy metal poisoning. In addition, succimer is able to chelate the alpha particle emitter and radionuclide polonium Po 210 ((Po-210), thereby increasing its excretion and reducing the toxic effects of Po-210.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E9BFEC6-1EAA-5D1C-E063-731AD00A1DFB","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EC3-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Zinc DTPA IV","valueDescription":null,"ValueMeaning":{"publicId":"14675081","version":"1","preferredName":"Intravenous Route of Administration Pentetate Zinc","longName":"14675081v1.00","preferredDefinition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index._The zinc salt form of diethylene triamine pentaacetate (Zn-DTPA or pentetate zinc) with chelating activity. Upon administration, Zn-DTPA loses the Zn ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Zn ions. Specifically, this agent is able to bind to and form strong complexes with the radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pentetate Zinc","conceptCode":"C120570","definition":"The zinc salt form of diethylene triamine pentaacetate (Zn-DTPA or pentetate zinc) with chelating activity. Upon administration, Zn-DTPA loses the Zn ion to form stable chelates with metal ions because DTPA has a higher affinity for heavy metal ions than for Zn ions. Specifically, this agent is able to bind to and form strong complexes with the radioactive plutonium, americium, and cerium after internal contamination. The formation of these heavy metal chelates enhances radionuclide excretion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E9BFEC6-1EAB-5D1C-E063-731AD00A1DFB","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EC4-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"},{"value":"Other","valueDescription":null,"ValueMeaning":{"publicId":"6431768","version":"1","preferredName":"Other","longName":"6431768v1.00","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"762A692A-EEF7-29A1-E053-F662850A9EA9","latestVersionIndicator":"Yes","beginDate":"2018-09-18","endDate":null,"createdBy":"WINCHC","dateCreated":"2018-09-18","modifiedBy":"GDEEN","dateModified":"2024-01-22","changeDescription":null,"administrativeNotes":"2023.2.1 Alt VM added per ticket request CADSR0001995. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E9BFEC6-1EC5-5D1C-E063-731AD00A1DFB","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"14675067","version":"1","preferredName":"Radionuclide Decorporation Agent Type","preferredDefinition":"Any agent that is able to prevent absorption or facilitate the removal of internal radionuclide contamination._Something distinguishable as an identifiable class based on common qualities.","longName":"14675067v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radionuclide Decorporation Agent","conceptCode":"C120558","definition":"Any agent that is able to prevent absorption or facilitate the removal of internal radionuclide contamination.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E9BE822-2769-594A-E063-731AD00AFCB4","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"0E9BE822-276A-594A-E063-731AD00AFCB4","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"What was the decorporation agent that was administered?","url":null,"context":"NHLBI"},{"name":"NMDP Text 1","type":"Application Standard Question Text","description":"Decorporation drugs","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"0E9C0D90-DA43-5FE1-E063-731AD00AA2FC","latestVersionIndicator":"Yes","beginDate":"2024-01-10","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2024-01-10","modifiedBy":"KUMMEROA","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":"2024.1.10 Created per ticket request CADSR0003268. ak","unresolvedIssues":null,"deletedIndicator":"No"}}